REGENERON PHARMACEUTICALS INC. - COMMON STOCK

Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases

25 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO

24 Apr 2024 10:05:18 By Nasdaq GlobeNewswire

Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT)

22 Apr 2024 17:54:01 By Nasdaq GlobeNewswire

Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma

07 Apr 2024 16:00:12 By Nasdaq GlobeNewswire

Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 2, 2024

01 Apr 2024 16:05:00 By Nasdaq GlobeNewswire

Regeneron Provides Update on Biologics License Application for Odronextamab

25 Mar 2024 07:00:02 By Nasdaq GlobeNewswire

High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization

12 Mar 2024 21:30:22 By Nasdaq GlobeNewswire

Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol

11 Mar 2024 07:00:23 By Nasdaq GlobeNewswire

EYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) Published in The Lancet

08 Mar 2024 07:00:26 By Nasdaq GlobeNewswire

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

28 Feb 2024 09:48:56 By NetDania Notify

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

26 Feb 2024 09:48:37 By NetDania Notify

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

23 Feb 2024 09:45:04 By NetDania Notify

Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflammation

23 Feb 2024 01:00:00 By Nasdaq GlobeNewswire

Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review

21 Feb 2024 07:00:13 By Nasdaq GlobeNewswire

Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU)

16 Feb 2024 00:59:00 By Nasdaq GlobeNewswire

Regeneron Announces Investor Conference Presentations

06 Feb 2024 16:05:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

02 Feb 2024 09:45:10 By NetDania Notify

Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results

02 Feb 2024 06:30:01 By Nasdaq GlobeNewswire

Linvoseltamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple Myeloma

02 Feb 2024 06:00:04 By Nasdaq GlobeNewswire

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

31 Jan 2024 09:45:04 By NetDania Notify